Scancell Share Discussion Threads

[plasybryn] 10/7/2024 10:28

Bargain under 10p. Who would have believed we could still buy in single figures.

[2tyke] 10/7/2024 10:02

Still thought I'd buy some under 10p...
Up already !

[2tyke] 10/7/2024 08:25

It'd make no difference to the share price if they put Taylor Swift on the board and wrote about it in the Daily mail.

[marcusl2] 10/7/2024 08:19

I agree Mia and found it surprising that they did not have someone already on the board.

Maybe a big deal or offer is brewing.

[rogerbridge] 10/7/2024 07:53

Excellent news and confirmation that we have something very valuable,

[miavoce] 10/7/2024 07:53

IMO a strong signal that we are entering a critical period for significant commercial activity. Redmile want skin in the game presumably to ensure the best outcome for themselves.

[pharmaboy3] 10/7/2024 07:24

Big hitter appointed to the board.HTTps://www.voxmarkets.co.uk/rns/announcement/36ef5263-052c-42a3-b6e5-349489dd0606

[sci102] 10/7/2024 07:10

Sci1022 Jul '24 - 07:25 - 426 of 438
Seems like a vote of confidence from Redmile, then again I'm not a finance person. Will be interesting to see if there are any operational changes in the next period.

-----

Expect more than just a Redmile professional on the board. Hopefully for the best for shareholders and company.

PS the only way my tone will change is if I see an experienced CEO taking over from LD, she should focus on the science and leave the rest to people who actually know what they are doing.

[sci102] 10/7/2024 05:56

"A larger trial will be ready by the end of this year and further studies are expected thereafte"

Nonsense, the adaptive phase 2/3 will start end of 2025 at the earliest. More likely H1 2026.

Hopefully an exit opportunity will present itself in the next couple of months.

[marcusl2] 09/7/2024 22:13

"clinical data is looking really really strong. Vaccines are going to be pretty huge.They will work some day, I think I`m there."

[markingtime] 09/7/2024 21:05

Remember the slip of the tongue at the end of the recent interview. I think Lindy really does believe she has "cracked it".

[marcusl2] 09/7/2024 19:38

Nothing yet Plasybryn!

Good data and interest from big pharma, maybe a takeover should do the job though.

[plasybryn] 09/7/2024 16:55

Like that Marcus. MSM coverage ought to attract some investors.

[marcusl2] 09/7/2024 14:00

WTP
Investors in Ozempic have made huge profits. Now our stock-picking expert unearths the companies working on the blockbuster treatments of the future - which could make you a packet

This is Money, Daily Mail 9th July


Scancell
Britain is widely recognised as a healthcare powerhouse with firms champing at the bit to produce blockbuster sales.

Many are in the cancer field. Despite the hype around Ozempic, the market for cancer drugs is at least three times bigger than its weight-loss counterpart and expected to remain so for years.

Already generating sales of almost £175billion a year, revenues from cancer treatments are forecast to more than double this decade and carry on rising thereafter.

Immunologist Professor Lindy Durrant and her team have developed a vaccine in a bid to find a cure for advanced skin cancer


That leaves room for plenty of blockbusters and Scancell is hoping to create one of them.

Founded by immunologist Professor Lindy Durrant, the company is developing a cure for advanced skin cancer and early signs are highly encouraging.

The treatment combines a vaccine developed by Durrant and her team with two widely available drugs. Trials to date have shown an 85 per cent success rate, far outweighing alternative approaches and better than Durrant ever imagined.

Vaccines are usually associated with disease prevention, from smallpox to measles to Covid.

Cancer vaccines are different. They aim to stimulate the body's immune system so that it produces cells that will fight and destroy cancer tumours.

Researchers have been trying to develop an effective vaccine for years but cancer keeps outwitting them.

Durrant's Eureka moment came when she decided to try a combination approach, blending her immune-system-boosting vaccine with drugs that allow the medicine to enter tumorous cells and do their magic.

The treatment has already proved successful on a small group of patients. A larger trial will be ready by the end of this year and further studies are expected thereafter.

Drug trials can take years but Durrant should be able to move faster, as her treatment could prove a lifesaver. There is also the possibility of moving into other forms of cancer, which could help millions of people worldwide.

Existing cancer treatments tend to be extremely expensive, riddled with side-effects or both. Scancell's therapy is simple to make, easier on the body than alternatives and a lot cheaper too.

Midas verdict: Scancell shares, which are listed on the junior AIM market, are less than 12p today. The company has been through tough times and nothing is certain in the world of drug research. But Durrant has more than 40 years' experience in the cancer field. She is a renowned professor at Nottingham University and believes she is on to a winner. If she is right, Scancell could fly - and that makes the shares well worth considering.

[2tyke] 09/7/2024 13:17

Greed ?
Think it's called ' trying to catch a falling knife....
Try stupidity...

[the real lozan] 09/7/2024 13:14

"Lozan lives in cuckoo land " -
Have today spent the morning with Allan, who has delivered a wagon load of excellent Oak logs... now baking in the sun 37 C... for winter fuel.
Not for this coming winter - Already have plenty of dry logs stocked
Which do WE ALL think might provide a better return on the investment =
Our logs / probable comfort
OR
Even more GREED pumped in to Scancell... I Bought again yesterday ???
.
Other than GREED...Why the need to keep buying ???
Why the NEED to keep telling everyone about it ???

[inanaco] 09/7/2024 10:06

Labour finds growth at last

Blair predicts £50bn Labour tax raid
Chief economist at the ex-PM’s institute forecasts taxes will have to go up by 1.9 percentage points of GDP by end of Parliament

Lozan finds he lives in cuckoo land led by Macron & the Communists ...

I will watch from a far probably from a Tax Haven

Scancell is doing ok I Bought again yesterday

[inanaco] 09/7/2024 09:56

good to see Modi3 .....................

the pipeline widens again

[marcusl2] 09/7/2024 09:24

https:
//tgf-beta-summit.com/about/about-event/

4th TGF-β Targeted Drug
Development Summit

[sci102] 09/7/2024 08:23

Actual Bid is currently 9.22. But yeah all is good🤣

[marcusl2] 08/7/2024 22:33

Lilly will acquire all outstanding shares of Morphic for approximately $3.2 billion.



small molecule inhibitor of α4β7 in Phase II
Rest is pre-clinical.

[sci102] 08/7/2024 15:56

I like your new outfit Marcus. Oops is that a boob slip? Shame Marcus. Shame.

[marcusl2] 08/7/2024 15:47

moonpartyStrong Buy
One that I particularly like, that I feel went under the radar, is the recent ModiFY update from May. This is the quote from LD included int he RNS:

"We greatly appreciate the supportive and helpful discussions with the MHRA and are thrilled to have received approval to expand ModiFY into a cohort of patients who will now receive Modi-1 in combination with double checkpoint inhibitors. This approval marks another milestone for Scancell, and the promising efficacy, safety and tolerability study generated from earlier cohorts underscore our belief that our Modi-1 cancer vaccine has the potential to deliver a step change in the treatment of renal and other hard-to-treat cancers."

[sci102] 08/7/2024 14:23

"Good news" means nothing if people think it's BS. Is the remaining patent life of iscib1+ 18 years like the CEO said or 15 years like the CFO said in the latest 2 presentations/interviews?

As for redmile, my view is that it's a vote of confidence but the truth is we don't know what their plans are and combined with the chronic inconsistency of the management, none of that inspires confidence. As simple as that.